ASLN Aslan Pharmaceuticals ADS

ASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference

ASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference

SAN MATEO, Calif. and SINGAPORE, Nov. 21, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to participate in a fireside chat at the Piper Sandler Healthcare Conference on Thursday, December 1, 2022, at 8:30am ET. The conference will be held from November 29 to December 1, 2022, in-person at the Lotte New York Palace Hotel, New York, NY.

A replay of the fireside chat will be made available on the  section of ASLAN’s website and can be accessed directly at .

Management will be available for one-on-one meetings with investors throughout the conference. Please contact your representative at Piper Sandler to schedule a meeting.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and farudodstat, a potent oral inhibitor of the enzyme DHODH, in autoimmune disease. ASLAN has a team in California and in Singapore. For additional information please visit  or follow ASLAN on .

Media and IR contacts

Emma Thompson

Spurwing Communications

Tel:

Email:

Ashley R. Robinson

LifeSci Advisors, LLC

Tel: +1 (617) 430-7577

Email:    

 



EN
21/11/2022

Underlying

ASLNAslan Pharmaceuticals ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aslan Pharmaceuticals ADS

 PRESS RELEASE
Free
ASLN Aslan Pharmaceu...

ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation...

ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation Following a thorough review of all strategic alternatives, ASLAN Pharmaceuticals Pte Ltd, the sole operating subsidiary of ASLAN Pharmaceuticals, has filed for voluntary liquidation Quantuma (Singapore) Pte Limited International has been appointed as the official liquidator and will seek potential strategic alternatives for the Company’s development programs, eblasakimab and farudodstat SAN MATEO, Calif. and SINGAPORE, Ju...

July 17, 2024 1 EN
 PRESS RELEASE
Free
ASLN Aslan Pharmaceu...

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determinat...

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal SAN MATEO, Calif. and SINGAPORE, July 15, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN” or the “Company”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that on July 9, 2024, the Company was notified by the staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that, based upon the Company’s non-compliance with the ...

July 15, 2024 1 EN
 PRESS RELEASE
Free
ASLN Aslan Pharmaceu...

ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change

ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change SAN MATEO, Calif. and SINGAPORE, June 14, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN” or the “Company”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to change the ratio of the American Depositary Shares (“ADSs”) to its ordinary shares, par value $0.01 per share, from one (1) ADS representing twenty-five (25) ordinary shares to one (1) ADS representing two hundred (200) ordinary sha...

June 14, 2024 1 EN
 PRESS RELEASE
Free
ASLN Aslan Pharmaceu...

ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Ebl...

ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference Translational data presented during a late-breaker poster session from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD indicates that eblasakimab performed better than dupilumab in improving airway function and enhancing bronchodilation at the same concentrations Results support further investigation of eblasakimab as a potential therapeutic option for COPD with potentially more effective blockade of Type-2 mediate...

May 21, 2024 1 EN
 PRESS RELEASE
Free
ASLN Aslan Pharmaceu...

ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and...

ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update Positive interim data readout from 22 patients in TREK-DX study of eblasakimab showed unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab-experienced AD patients treated with 400mg eblasakimab weekly achieved EASI-90 (at least a 90% reduction in their Eczema Area Severity Index (EASI) score) and 66.7% achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks, versus 14.3% of patients on placebo. On track to report to...

May 9, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch